Physostigmine: Difference between revisions
ClaireLewis (talk | contribs) |
No edit summary |
||
| Line 9: | Line 9: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*.02mg/kg repeat every 5-10 minutes until adequate response, max of 2mg | *.02mg/kg repeat every 5-10 minutes until adequate response, max of 2mg | ||
*no faster than .5mg/min | *no faster than .5mg/min | ||
| Line 38: | Line 37: | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 06:42, 13 July 2017
General
- Type: acetylcholinesterase inhibitor
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Anticholinergic toxicity
- 0.5-2mg IV over 5min
Pediatric Dosing
- .02mg/kg repeat every 5-10 minutes until adequate response, max of 2mg
- no faster than .5mg/min
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Side effects: bradycardia, dysrhythmias, cholinergic excess
- Always have atropine at the bedside for bradycardia or cholinergic excess
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
- Onset of action: 15-20min